Genmab's Epcoritamab Extends Survival in DLBCL Patients, Stock Drops 7%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Clinical Trial Results: Genmab's bispecific antibody Epcoritamab demonstrated potential to extend progression-free survival in late-stage diffuse large B-cell lymphoma (DLBCL) patients in a Phase 3 trial, yet the lack of statistically significant overall survival improvement led to a 7% drop in stock price, reflecting investor concerns.
- Improved Patient Response Rates: In a global trial involving 483 relapsed/refractory DLBCL patients who had undergone at least one prior therapy, Epcoritamab as a monotherapy improved complete response rates and duration of response, indicating its therapeutic potential despite not achieving overall survival significance.
- FDA Accelerated Approval: Epcoritamab is currently available in the U.S. under the FDA's accelerated approval pathway for DLBCL patients who have relapsed or failed to respond to two or more treatments, highlighting its market relevance and potential commercial opportunity.
- Future Regulatory Discussions: Genmab plans to meet with global regulators to discuss next steps for the program, demonstrating the company's commitment to further developing Epcoritamab, even as current clinical results fell short of market expectations.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 248.67 USD with a low forecast of 204.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
24 Analyst Rating
15 Buy
9 Hold
0 Sell
Moderate Buy
Current: 216.750
Low
204.00
Averages
248.67
High
289.00
Current: 216.750
Low
204.00
Averages
248.67
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
